Skip Navigation



Annals of Oncology Advance Access published online on February 23, 2006
Annals of Oncology, doi:10.1093/annonc/mdl005
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/4/652    most recent
mdl005v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Giordano, K. F.
Right arrow Articles by Nikcevich, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giordano, K. F.
Right arrow Articles by Nikcevich, D. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received September 29, 2005
Revised December 22, 2005
Accepted December 27, 2005

original article

Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group

K. F. Giordano 1, A. Jatoi 1 *, P. J. Stella 2, N. Foster 1, L. K. Tschetter 3, S. R. Alberts 1, S. R. Dakhil 4, J. A. Mailliard 5, P. J. Flynn 6, and D. A. Nikcevich 7

1 Mayo Clinic and Mayo Foundation, Rochester, MN, USA
2 Michigan Cancer Consortium, Ann Arbor, MI, USA
3 Sioux Valley Clinic Oncology, Sioux Falls, SD, USA
4 Wichita Community Clinical Oncology Program, Wichita, KS, USA
5 Missouri Valley Cancer Consortium, Omaha, NE, USA
6 Metro-Minnesota Community Oncology Program, St. Louis Park, MN, USA
7 Duluth CCOP, Duluth, MN, USA

* To whom correspondence should be addressed.
A. Jatoi, E-mail: Jatoi.aminah{at}mayo.edu


  Abstract

Background: Previous studies suggest that the combination of docetaxel and capecitabine are worthy of further testing in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction. We therefore undertook this phase II study to test this combination in a multi-institutional, first-line clinical trial.

Patients and methods: Forty-four eligible patients with histologic or cytologic confirmation of the above malignancy were recruited. The cohort had Eastern Cooperative Oncology Group performance scores of 0, 1 and 2 in 59%, 39% and 2% of patients, respectively. Median age was 57 years (range 32-77 years). Adequate organ function was a requirement for study entry. All patients were prescribed docetaxel 75 mg/m2 intravenously on day 1 and capecitabine 825 mg/m2 orally twice a day on days 1-14 of a 21-day cycle.

Results: The tumor response rate was 39% [95% confidence interval (CI) 23% to 55%]. There were two complete responses and the rest were partial. Median survival was 9.4 months (95% CI 6.3-10.7 months) and median time-to-tumor progression was 4.2 months (95% CI 3.6-5.6 months). There was one treatment-related death from a myocardial infarction and dysrhythmia. Commonly occurring grade 3 adverse events included neutropenia (11 patients), infection (five patients), constipation (three patients), thrombosis (three patients), dyspnea (three patients) and hand-foot syndrome (three patients). In addition, 24/45 patients developed grade 4 neutropenia.

Conclusions: The regimen docetaxel and capecitabine shows activity in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction. This regimen merits further study.

Keywords: capecitabine; chemotherapy; docetaxel; gastric cancer; gastroesophageal junction; stomach.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
N. Starling, S. Rao, D. Cunningham, T. Iveson, M. Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates, and A. R. Norman
Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group
J. Clin. Oncol., August 10, 2009; 27(23): 3786 - 3793.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. C. Enzinger, D. P. Ryan, J. W. Clark, A. Muzikansky, C. C. Earle, M. H. Kulke, J. A. Meyerhardt, L. S. Blaszkowsky, A. X. Zhu, P. Fidias, et al.
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer
Ann. Onc., March 1, 2009; 20(3): 475 - 480.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M Orditura, E Martinelli, G Galizia, C Carlomagno, G Aurilio, L Vecchione, E. Lieto, S De Placido, G Catalano, F Ciardiello, et al.
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study
Ann. Onc., October 1, 2006; 17(10): 1529 - 1532.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.